Evidence map›Paper›PMID 23607541›Full record

ArticleMalaria journal2013

Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine.

Margaret E McCoy, Hannah E Golden, Tais Apf Doll, Yongkun Yang, Stephen A Kaba, Xiaoyan Zou, Vincent R Gerbasi, Peter Burkhard, David E Lanar

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Malaria journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 57 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
    Zou, Xiaoyan [added]; Gerbasi, Vincent R [added]
5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Margaret E McCoyMalaria Vaccine Branch, WRAIR, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA.
Hannah E Golden
Tais Apf Doll
Yongkun Yang
Stephen A Kaba
Xiaoyan Zou
Vincent R Gerbasi
Peter Burkhard
David E Lanar
Walter Reed Army Institute of Research · USUniversity of Connecticut · US

Funding

Malaria Vaccine Based on Self-Assembling Polypeptide Nanoparticles (SAPN)R01AI068761 · NIAID · UNIVERSITY OF CONNECTICUT STORRS · PI BURKHARD, PETER, LANAR, DAVID ERVIN · 2009 to 2012
$2.1M
NIAID NIH HHS 1R01AI068761-01A2
6 · The paper itself

Abstract

backgroundA lack of defined correlates of immunity for malaria, combined with the inability to induce long-lived sterile immune responses in a human host, demonstrate a need for improved understanding of potentially protective immune mechanisms for enhanced vaccine efficacy. Protective sterile immunity (>90%) against the Plasmodium falciparum circumsporozoite protein (CSP) has been achieved using a transgenically modified Plasmodium berghei sporozoite (Tg-Pb/PfCSP) and a self-assembling protein nanoparticle (SAPN) vaccine presenting CSP epitopes (PfCSP-SAPN). Here, several possible mechanisms involved in the independently protective humoral and cellular responses induced following SAPN immunization are described.

methodsInbred mice were vaccinated with PfCSP-SAPN in PBS. Serum antibodies were harvested and effects on P. falciparum sporozoites mobility and integrity were examined using phase contrast microscopy. The functionality of SAPN-induced antibodies on inhibition of sporozoite invasion and growth within primary human hepatocytes was also examined. The internal processing of SAPN by bone marrow-derived dendritic cells (BMDDC), using organelle-specific, fluorescent-tagged antibody or gold-encapsulated SAPN, was observed using confocal or electron microscopy, respectively.

resultsThe results of this work demonstrate that PfCSP-SAPN induces epitope-specific antibody titers, predominantly of the Th2 isotype IgG1, and that serum antibodies from PfCSP-SAPN-immunized mice appear to target P. falciparum sporozoites via the classical pathway of complement. This results in sporozoite death as indicated by cessation of motility and the circumsporozoite precipitation reaction. Moreover, PfCSP-SAPN-induced antibodies are able to inhibit wild-type P. falciparum sporozoite invasion and growth within cultured primary human hepatocytes. In addition, the observation that PfCSP-SAPN are processed (and presented) to the immune system by dendritic cells in a slow and continuous fashion via transporter associated with antigen processing (TAP) recruitment to the early endosome (EE), and have partially delayed processing through the endoplasmic reticulum, has the potential to induce the long-lived, effector memory CD8+ T-cells as described previously.

conclusionThis paper describes the examination of humoral and cellular immune mechanisms induced by PfCSP-SAPN vaccination which result in sterile host protection against a transgenic P. berghei malaria sporozoite expressing the P. falciparum CSP, and which significantly inhibits native P. falciparum sporozoites from invading and developing within cultured human hepatocytes. These results may indicate the type and mode of action of protective antibodies needed to control P. falciparum sporozoites from infecting humans as well as a potential mechanism of induction of protective long-lived effector memory CD8+ T-cells.

Indexed as

NanoparticlesAnimalsAntibodies, ProtozoanCD8-Positive T-LymphocytesDendritic CellsFemaleHepatocytesMalaria VaccinesMiceMice, Inbred C57BLPlasmodium bergheiPlasmodium falciparumProtozoan ProteinsVaccines, SubunitVaccines, SyntheticAntibodies, Protozoancircumsporozoite protein, ProtozoanMalaria VaccinesProtozoan ProteinsVaccines, SubunitVaccines, Synthetic

Identifiers

PMID23607541
PMCPMC3765086
OpenAlexW2166250704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.